Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials

We previously identified a human leukocyte antigen (HLA)-A24-restricted antigenic peptide, survivin-2B80–88, a member of the inhibitor of apoptosis protein family, recognized by CD8+cytotoxic T lymphocytes (CTL). In a phase I clinical trial of survivin-2B80-88 vaccination for metastatic urothelial c...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Toshiaki, Kitamura, Hiroshi, Inoue, Ryuta, Nishida, Sachiyo, Takahashi-Takaya, Akari, Kawami, Sachiyo, Torigoe, Toshihiko, Hirohashi, Yoshihiko, Tsukamoto, Taiji, Sato, Noriyuki, Masumori, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863714/
https://www.ncbi.nlm.nih.gov/pubmed/24363758
http://dx.doi.org/10.1155/2013/262967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863714/
https://www.ncbi.nlm.nih.gov/pubmed/24363758
http://dx.doi.org/10.1155/2013/262967

Ejemplares similares